16.71
+0.44(+2.70%)
Currency In USD
| Previous Close | 16.27 |
| Open | 16.68 |
| Day High | 16.98 |
| Day Low | 16.34 |
| 52-Week High | 46.36 |
| 52-Week Low | 11.87 |
| Volume | 128,168 |
| Average Volume | 270,412 |
| Market Cap | 428.49M |
| PE | -6.71 |
| EPS | -2.49 |
| Moving Average 50 Days | 16.02 |
| Moving Average 200 Days | 18.9 |
| Change | 0.44 |
If you invested $1000 in Tourmaline Bio, Inc. (TRML) since IPO date, it would be worth $231.5 as of March 13, 2025 at a share price of $16.71. Whereas If you bought $1000 worth of Tourmaline Bio, Inc. (TRML) shares 3 years ago, it would be worth $498.21 as of March 13, 2025 at a share price of $16.71.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025
GlobeNewswire Inc.
Mar 03, 2025 12:15 PM GMT
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune a
Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference
GlobeNewswire Inc.
Jan 27, 2025 12:00 PM GMT
NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune an
Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker
GlobeNewswire Inc.
Jan 10, 2025 12:30 PM GMT
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune an